Magnesium Deficiency in Chronic Schizophrenia

References

• Alexander P. E., Van Kammen D. P., Bunney W. E. Serum calcium and magnesium in schizophrenia: Relationship to clinical phenomena and neuroleptic treatment. British Journal of Psychiatry 1978; 133: 143–149
   PubMedGoogle Scholar
• Alexander P. E., Van Kammen D. P., Bunney W. E. Serum calcium and magnesium levels in schizophrenia. Possible relationship to extrapyramidal symptoms. Archives of General Psychiatry 1979; 36: 1372–1377
   PubMedGoogle Scholar
• Athanassenas G., Papadopoulos E., Kourkoubas A., Tsitourides S. Serum calcium and magnesium levels in chronic schizophrenia. Journal of Clinical Psychopharmacology 1983; 3: 212–216
   PubMed Web of Science ®Google Scholar
• Bois P., Gascon P., Beaulnes A. Histamine liberating effects of magnesium deficiency in the rat. Nature 1963; 197: 501–502
   PubMed Web of Science ®Google Scholar
• Brackenridge C. J., Jones I. H. Relation of hypermagnesemia to activity and neuroleptic drug therapy in schizophrenic states. Journal of Neurology, Neurosurgery and Psychiatry 1971; 34: 195–199
   PubMedGoogle Scholar
• Buchanan R. W., Kirkpatrick B., Heinrichs D. W., Carpenter W. T. Clinical correlates of the deficit syndrome of schizophrenia. American Journal of Psychiatry 1990; 147: 290–294
   PubMed Web of Science ®Google Scholar
• Cade J. F. A significant elevation of plasma magnesium levels in schizophrenia and depressive states. Medical Journal of Australia 1964; 1: 195–196
   PubMedGoogle Scholar
• Smith L. H. Disorders of magnesium metabolism. Cecil Textbook of medicine, 18th Ed. W. B. Saunders, Philadelphia 1988; 1195–1196
   Google Scholar
• Chutkow J. G., Grabow J. D. Clinical and chemical correlations in magnesium-deprivation encephalopathy of young rats. American Journal of Physiology 1972; 223: 1407–1414
   PubMed Web of Science ®Google Scholar
• Csernansky I. G., King R. J., Faustman W. O., Moses J. A., Poscher M. E., Faull K. F. 5-HIAA in cerebrospinal fluid and deficit schizophrenic characteristics. British Journal of Psychiatry 1990; 156: 501–507
   PubMedGoogle Scholar
• Dakshinamurti K., LeBlancq W. D., Herchl R., Havlicek V. Nonparallel changes in brain monoamines of pyridoxine deficient growing rats. Experimental Brain Research 1976; 26: 355–366
   PubMedGoogle Scholar
• Dreyfus P. M., Geel S. E. Vitamin and nutritional deficiencies. Basic neurochemistry, G. J. Siegel, R. W. Albers, B. W. Agranoff, R. Katzman. Little Brown and Company, Boston 1981; 661–679
   Google Scholar
• Hall R. C. W., Joffe J. R. Hypomagnesemia. Physical and psychiatric symptoms. Journal of the American Medical Association 1973; 224: 1749–1751
   PubMed Web of Science ®Google Scholar
• Hubbard J. I. Microphysiology of vertebrate neuromuscular transmission. Physiological Review 1973; 53: 674–723
   PubMedGoogle Scholar
• Itokawa Y., Inoue K., Natori Y., Okazaki K., Fujiwara M. Effect of thiamine on growth, tissue magnesium, thiamine levels and transketolase activity in magnesium deficient rats. Journal of Vitaminology 1972; 18: 159–164
   PubMedGoogle Scholar
• Itokawa Y., Kimura M., Inagaki C., Tanaka C. Effect of thiamine on serotonin oxidation in magnesium deficient rats. Journal of Nutritional Science and Vitaminology 1974; 20: 27–33
   PubMedGoogle Scholar
• Jimerson D.C, Post R. M., Carman J. S., Van Kammen D. P., Wood J. H., Goodwin F. K., Bunney W. E. CSF calcium: clinical correlates in affective illness and schizophrenia. Biological Psychiatry 1979; 14: 37–51
   PubMed Web of Science ®Google Scholar
• Kandel E. R. Factors controlling transmitter release. Principles of neural science, E. R. Kandel, J. H. Schwartz. Elsevier, Amsterdam 1985; 120–131
   Google Scholar
• Kane J., Honigfeld G., Singer J., Meltzer H. Y., Group Collaborative Study. Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorproma-zine. Archives of General Psychiatry 1988; 45: 789–796, the Clozaril
   PubMed Web of Science ®Google Scholar
• Katz B., Miledi R. The timing of calcium action during neuromuscular transmission. Journal of Physiology 1967; 189: 535–544
   PubMed Web of Science ®Google Scholar
• Martin P. R., Higa S., Bums S., Tamarkin L., Ebert M. H., Markey S. P. Decreased 6-hydroxymelatonin excretion in Korsakoff's psychosis. Neurology 1984; 34: 966–968
   PubMedGoogle Scholar
• Meltzer H. Y. The role of serotonin in the action of atypical antipsychotic drugs. Psychiatric Annals 1990; 10: 571–579
   Google Scholar
• Paulose C. S., Dakshinamurti K. Effect of pyridoxine deficiency in young rats on high-affinity serotonin and dopamine receptors. Journal of Neuroscience Research 1985; 14: 263–270
   PubMed Web of Science ®Google Scholar
• Plaitakis A., Nicklas W. J., Berl S. Thiamine deficiency: selective impairment of cerebellar serotonergic system. Neurology 1978; 28: 691–698
   PubMed Web of Science ®Google Scholar
• Potkin S. G., Weinberger D. R., Linnoila M., Wyatt R. J. Low CSF 5-hydroxyindoleacetic aciud in schizophrenic patients with enlarged cerebral ventricles. American Journal of Psychiatry 1983; 140: 21–25
   PubMed Web of Science ®Google Scholar
• Sandyk R., Pardeshi R. Pyridoxine improves drug-induced Parkinsonism and psychosis in a schizophrenic patients. International Journal of Neuroscience 1990; 52: 225–232
   PubMed Web of Science ®Google Scholar
• Seelig M. S., Berger A. R., Spielholz N. Latent tetany and anxiety, marginal magnesium deficit, and normocalcemia. Diseases of the Nervous System 1975; 36: 461–465
   PubMedGoogle Scholar
• Seelig M. S. Nutritional status and requirements of magnesium with considerations of individual differences and prevention of cardiovascular disease. Magnesium Bulletin 1986; 8: 171–185
   Google Scholar
• Shils M. E. Experimental human magnesium depletion. Medicine 1969; 48: 61–85
   PubMed Web of Science ®Google Scholar
• Shils M. E. Magnesium. Modern nutrition in health and disease, M. E. Shils, V. R. Young. Lea & Fibiger, Philadelphia 1988; 159–192
   Google Scholar
• Stephens M.C, Havlicek V., Dakshinamurti K. Pyridoxine deficiency and development of the central nervous system in the rat. Journal of Neurochemistry 1971; 18: 2407–2416
   PubMedGoogle Scholar
• Tandon R., Greden J. F. Cholinergic hyperactivity and negative schizophrenic symptoms. A model of cholinergic/dopaminergic interactions in schizophrenia. Archives of General Psychiatry 1989; 46: 745–753
   PubMed Web of Science ®Google Scholar
• Vinswanathan M., Siow Y. L., Paulose C. S., Dakshinamurti K. Pineal indole metabolism in pyridoxine-deficient rats. Brain Research 1988; 473: 37–42
   PubMedGoogle Scholar